Your browser doesn't support javascript.
loading
Validation of the NCCN-IPI and the GELTAMO-IPI for diffuse large B-Cell lymphoma treated with R-CHOP in a large cohort of patients from a single institution.
Salas, María Queralt; Mercadal, Santiago; Domingo Domenech, Eva; Oliveira, Ana Carla; Encuentra, Maite; Climent, Fina; Andrade Campos, Marcio; Aguilera, Carmen; Fernández de Sevilla, Alberto; Sureda, Anna; González-Barca, Eva.
Afiliación
  • Salas MQ; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Mercadal S; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Domingo Domenech E; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Oliveira AC; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Encuentra M; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Climent F; Department of Pathology, University Hospital of Bellvitge-IDIBELL, Barcelona, Spain.
  • Andrade Campos M; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Aguilera C; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Fernández de Sevilla A; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • Sureda A; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
  • González-Barca E; Department of Clinical Haematology, Institut Català Oncologia (ICO)-Hospitalet, Barcelona, Spain.
Leuk Lymphoma ; 61(3): 575-581, 2020 03.
Article en En | MEDLINE | ID: mdl-31684781
The discriminative power of International Prognostic Index (IPI) in diffuse large B-cell lymphoma (DLBCL) decreased with the addition of rituximab to chemotherapy. The National Comprehensive Cancer Network (NCCN)-IPI and the Grupo Español de Linfomas y Trasplante Autólogo de Médula Ósea (GELTAMO)-IPI were developed to improve the risk prediction for DLBCL patients. We aim to validate the NCCN-IPI and GELTAMO-IPI in a large and homogeneous cohort of 337 DLBCL patients treated with curative intent with R-CHOP/R-CHOP-like immunochemotherapy. The IPI stratifies patients in two independent risk groups and the estimated 5-year overall survival (OS) of the high-risk (HR) group was 43%. NCCN-IPI discriminated four risk groups and GELTAMO-IPI three risk groups of patients. The predicted 5-year OS of the HR group was 38% and 29%, respectively. NCCN-IPI and GELTAMO-IPI are more accurate prognostic indices than IPI in DBLCL patients treated with immunochemotherapy. GELTAMO-IPI demonstrated enhanced discrimination than NCCN-IPI for the higher-risk population.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Linfoma de Células B Grandes Difuso Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos